001: LBH589 mouse 12.29 ± 7.22 versus 4.43 ± 1.17%, respectively) (Fig. 1A). When we compared active (n = 4) to inactive SLE patients (n = 17), we did not find differences for the basal expression (10.20 ± 4.10 versus 7.01 ± 6.65%, P = 0.34) or after stimulation (19.25 ± 7.19 versus 10.14 ± 5.96%, P = 0.06) (Fig. 1B). Figure 1C shows a histogram of CD30-expressing T cells of a healthy control in basal conditions (0.58% of positive cells),

and Fig. 1D shows the same sample after stimulation (4.22% of positivity). The lower histogram presents the profile of an inactive SLE patient without stimulation with 8.10% of positive CD3 T cells for CD30 expression (Fig. 1E). To investigate the proportion of positive CD4 and CD8 T cells which expressed CD30, we performed two-colour immunofluorescence staining with CD30-PE and CD4-FITC. The percentage of positive CD30-CD8 T cells was indirectly calculated from the difference between the CD30+-CD3 and CD30+-CD4 T cells. No differences were found in the percentage of CD30-CD4 and CD30-CD8 T cells in controls (P > 0.05): 0.53 ± 0.23 versus 0.60 ± 0.33%, respectively

(Table 1). However, a higher percentage of CD30-CD8 T cells with regard to CD30-CD4 T cells (4.43 ± 3.60 versus 2.88 ± 3.10%; respectively, P = 0.023) in non-stimulated cells from patients with SLE (n = 21) was found (Table 1). The percentage of positive CD3 T cells producing IL-4, IFNγ, IL-10 and TGFβ was higher in basal samples from patients with SLE (n = 21) than in healthy controls (P < 0.05) (Fig. 2A). The expression of cytokines was very low in basal samples of healthy controls, presenting INCB024360 clinical trial the major differences in TGFβ expression compared to the remaining ones (P < 0.05) (Fig. 2C). However, the expression of all of them was importantly enhanced after cell stimulation next (Fig. 2B), where healthy controls showed the highest percentage of IFNγ-producing

CD3 T cells expression (P = 0.031) (Fig. 2B). As shown in agreement with previous reports [20], IFNγ (5.02 ± 4.03%) has a higher expression in comparison with IL-4 (1.43 ± 0.56%, P = 0.004) and IL-10 (1.31 ± 0.71%, P = 0.002), but not with TGFβ (2.85 ± 1.25%, P = 0.280) (Fig. 2C). However, in samples from patients with SLE in basal conditions, TGFβ (0.63 ± 0.19%) was the cytokine with the highest expression with significant differences when compared to IL-4 (0.32 ± 0.29%, P = 0.009) and IFNγ (0.37 ± 0.47%, P = 0.01) (Fig. 2D). In contrast to the controls, TGFβ (3.66 ± 2.06%) also showed the highest expression level in the CD3-stimulated lymphocytes from patients with SLE, showing statistical differences in comparison with IL-4 (1.48 ± 0.88%, P = 0.001), IL-10 (1.99 ± 1.06%, P = 0.001) and IFNγ (2.25 ± 1.02%, P = 0.006) (Fig. 2D). Dot plots in Fig. 3 present the percentage of positive CD3 T cells after stimulation for TGFβ staining in an inactive SLE patient (A, 4.56%) and for IFNγ in a healthy control (B, 8.32%).